Richards, Duncan

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double‐blind, randomised, placebo‐controlled, crossover, phase 2a study

Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 206

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

Richards, D. B., Cookson, L. M., Barton, S. V., Liefaard, L., Lane, T., Hutt, D. F., Ritter, J. M., Fontana, M., Moon, J. C., Gillmore, J. D., et al. (2018) · Science Translational Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesPrion Diseases and Protein Misfolding

Cited by 136

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hayward, G., Yu, L.-M., Little, P., Gbinigie, O., Shanyinde, M., Harris, V., Dorward, J., Saville, B. R., Berry, N., Evans, P. H., et al. (2024) · Journal of Infection

COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19

Cited by 31

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

Sahota, T., Berges, A., Barton, S., Cookson, L., Zamuner, S., & Richards, D. (2015) · CPT: Pharmacometrics & Systems Pharmacology

Amyloidosis: Diagnosis, Treatment, OutcomesPharmaceutical studies and practices

Cited by 19